Welcome to our dedicated page for Avalo Therapeutics SEC filings (Ticker: AVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Avalo Therapeutics, Inc. (NASDAQ: AVTX) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, including Form 8-K current reports and other key documents. Avalo is a Delaware-incorporated clinical stage biotechnology company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, and its filings offer structured insight into both its clinical progress and corporate actions.
Recent Form 8-K filings referenced by the company cover a range of material events. These include announcements of quarterly financial results, where Avalo reports information such as cash, cash equivalents and short-term investments and summarizes research and development and general and administrative expenses. Other 8-Ks describe the posting of updated investor presentations, which outline the development strategy for AVTX-009 and the design of the Phase 2 LOTUS trial in hidradenitis suppurativa (HS).
Additional 8-K reports detail governance and executive changes, such as the appointment of new directors and the hiring of senior executives like a Chief Business Officer. These filings summarize board decisions, committee assignments, equity awards, employment agreement terms and director compensation under Avalo’s non-employee director compensation plan. They also document director resignations and related amendments to outstanding equity awards.
For investors analyzing AVTX-009 and Avalo’s HS program, SEC filings complement press releases by providing formal descriptions of the LOTUS trial, including its randomized, double-blind, placebo-controlled Phase 2 design, dosing regimens and primary and secondary endpoints. They also link to exhibits such as press releases and investor presentations that expand on the company’s IL-1β scientific rationale.
On Stock Titan, these filings are updated as they are made available through EDGAR. AI-powered tools help summarize lengthy documents, highlight key sections on financial condition, clinical development updates, executive compensation and equity incentives, and make it easier to locate items such as Form 8-K exhibits and other relevant disclosures related to Avalo’s immune-mediated inflammatory disease programs.
Avalo Therapeutics, Inc. reported the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. Boyd brings nearly 15 years of experience in biotech business development, corporate finance, and investment banking, including senior roles at Abzena and Longboard Pharmaceuticals, where he led significant M&A and licensing activity.
Under an employment agreement dated September 29, 2025, Boyd will receive a base salary of $465,000 and a discretionary annual bonus targeted at up to 40% of base salary, payable in cash or, if mutually agreed, immediately vested equity. As an inducement, he will be granted a stock option for 275,000 shares of Avalo common stock on October 1, 2025, with an exercise price equal to the Nasdaq closing price on the grant date and vesting over four years.
If Avalo terminates Boyd without Cause or he resigns for Good Reason, severance protections include continued salary for nine months (extended to 12 months if termination occurs within six months after a Change in Control), a prorated or enhanced bonus depending on timing, full vesting of outstanding options with six months to exercise, and up to 12 months of COBRA premium payments, all conditioned on a release of claims and compliance with confidentiality, non-disparagement, invention assignment, non-competition, and non-solicitation covenants.
Avalo Therapeutics, Inc. reported changes to its board of directors. The company’s board appointed Kevin Lind as a director effective October 1, 2025, and he will also join the Audit Committee, serving until the 2026 annual meeting or until a successor is elected and qualified.
In line with Avalo’s Amended and Restated Non-Employee Director Compensation Plan, Mr. Lind will receive a non-qualified stock option to purchase 40,200 shares of common stock on October 1, 2025, vesting in three equal annual installments, with an exercise price equal to that day’s Nasdaq Capital Market closing price.
June Almenoff, M.D., Ph.D. resigned as a director, effective October 1, 2025, to pursue new opportunities; her resignation, including from the Audit Committee, is stated as not related to the company’s operations, policies, or practices. Avalo is accelerating vesting of her outstanding equity awards as of October 1, 2025, and extending the expiration dates of her outstanding stock options to September 30, 2026.
Patrick J. Crutcher filed an amended Schedule 13G reporting beneficial ownership of 549,467 shares of Avalo Therapeutics, Inc. common stock, representing 4.2% of the 13,152,356 shares outstanding cited from the issuer's August 7, 2025 prospectus. The filing shows the Reporting Person holds sole voting and dispositive power over all reported shares and indicates the position is not held to change or influence control of the company. The filing includes the Reporting Person's address in Atlanta, GA, and a certification that the securities were not acquired in connection with any control transaction.
Avalo Therapeutics (AVTX) disclosed that OrbiMed Advisors LLC beneficially holds 967,000 shares of common stock, representing 8.9% of the class, with shared voting and dispositive power over those shares. OrbiMed Capital GP IX LLC separately reports beneficial ownership of 644,667 shares, or 6.0% of the class, also with shared voting and dispositive power. The filing states these holdings are exercised on behalf of other persons and that the reported shares were not acquired to change or influence control of the issuer. Key executives on the management committee are identified as exercising voting power.
Form 4 overview: Avalo Therapeutics, Inc. (AVTX) filed a Form 4 disclosing an equity-based compensation grant to board member Samantha Truex on 06/17/2025. The filing reports no sales or disposals of common stock; it solely records the award of new derivative securities.
Key terms of the option grant
- Security: Stock Option (Right to Buy) on AVTX common shares
- Underlying shares: 20,100
- Exercise price: $4.47 per share
- Vesting schedule: 100 % cliff vest on the first anniversary of the grant date, conditional on Ms. Truex’s continued board service
- Expiration: 06/17/2035 (10-year term)
- Ownership form after transaction: Direct
The transaction increases Ms. Truex’s derivative beneficial ownership to 20,100 options. No non-derivative (common stock) positions are listed in this filing, and there is no indication of Rule 10b5-1 trading plan use.
Investor takeaway: The filing reflects routine board compensation rather than market activity. While the additional options further align the director’s incentives with shareholders, the relatively small size (≈20 k shares) suggests limited immediate impact on AVTX’s share float or insider-sentiment signals.
Form 4 filing overview: On 18 June 2025, Avalo Therapeutics, Inc. (AVTX) reported that director Mitchell Chan received a new equity award on 17 June 2025. The grant consists of 20,100 non-qualified stock options with an exercise price of $4.47 per share, expiring 17 June 2035. The option vests 100 % on the first anniversary of the grant date, provided the director remains in service at that time.
Post-transaction holdings: Following the grant, Chan directly beneficially owns 20,100 derivative securities (options). No acquisitions or dispositions of common shares were reported in Table I, so the filing only affects derivative ownership.
Implications for investors: The award is a routine component of board compensation that aligns the director’s incentives with shareholder interests by linking future gains to share price appreciation above $4.47. Although the 20,100-share underlying amount represents minimal potential dilution relative to Avalo’s outstanding share count, it does marginally increase fully-diluted share capital. No cash outflow or immediate EPS impact occurs because the options are non-cash grants and forfeiture is possible if service ceases before vesting.
Materiality assessment: The transaction is not a signal of insider buying or selling; rather, it is a standard equity grant with no direct indication of management’s near-term outlook. Consequently, its market impact should be limited, but it demonstrates continued board engagement and retention efforts.